Tuesday, January 06, 2015 2:25:24 AM
The difference between version 1 and version 2 is mitogenic stimulation level and incubation time.
In version 1 the mitogenic stimulation PWM, 4 µg/mL with incubation time 4 hours before samples are analyzed using cytometer.
In version 2 the stimulation PWM, 8 µg/mL with incubation time of 20 hours before samples are analyzed.
Increased CD69 expression observed with higher concentrations of mitogenic stimulants and longer incubation times translated to greater univariate differentiation between Alzheimer’s subjects and those with other chronic progressive dementias.
Conclusion :
AMBS did trials based on specific parameters of PWM and incubation times. However they can change these parameters and get even better results by adjusting mitogenic stimulation levels and incubation times. It means they can get sensitivity higher than 90.
http://content.stockpr.com/amarantus/files/pdf/Poster+2+-+Clinical+FINAL_v2.pdf
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM